Pacira Pharmaceuticals sell JPMorgan Chase & Co.
Start price
12.08.24
/
50%
€11.10
Target price
12.08.25
€9.16
Performance (%)
36.04%
Price
03.10.24
€14.10
Summary
This prediction is currently active. The price for Pacira Pharmaceuticals has massively increased, which is bad news for the SELL prediction by JPMorgan_Chase___Co_. This prediction currently runs until 12.08.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 9.302% | 9.302% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock, down previously from $45.00.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€28.20
07.03.24
07.03.24
€41.38
07.03.25
07.03.25
-50.35%
03.10.24
03.10.24